Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Austco Healthcare Limited (AHC.AX)
Port Melbourne, VIC, AU
Austco Healthcare Limited, through its subsidiaries, operates as a global entity focused on the development, production, and comprehensive servicing of advanced healthcare and electronic communication systems. The company's market reach extends across Australia, New Zealand, Asia, Europe, and North America. A significant product in its portfolio is Tacera, an internet protocol (IP) based nurse call solution specifically engineered for both hospitals and aged care facilities. Originally founded in 1986, the company adopted its current name, Austco Healthcare Limited, in November 2020, having previously been known as Azure Healthcare Limited. Its corporate headquarters are located in Port Melbourne, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | -8.96% | -7.58% | -16.44% | -27.38% | -22.78% | +1.67% | +125.93% | +205.68% | +377.70% | +54.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+40.0% ★ Q4'25: +111.2% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-30.1% Q4'25: +223.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+5.8% Q4'25: +18.1% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.0% Q4'25: +13.3% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+19.0% ★ Q4'25: +37.7% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+19.9% Q4'25: +25.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.35× ★ Q4'25: 0.23× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 2 EPS Ana. |
Jun 2027 2 Rev. Ana. 2 EPS Ana. |
Jun 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
58.15M
est: 44.20M (+31.6%)
|
81.41M
est: 82.00M (-0.7%)
|
106.10M
105.70M – 106.50M
+29.4% YoY
|
115.65M
114.20M – 117.10M
+9.0% YoY
|
124.35M
123.31M – 125.39M
+7.5% YoY
|
| EBITDA |
8.11M
est: 5.53M (+46.6%)
|
11.10M
est: 10.26M (+8.1%)
|
13.28M
13.23M – 13.33M
+29.4% YoY
|
14.48M
14.30M – 14.66M
+9.0% YoY
|
15.57M
15.44M – 15.70M
+7.5% YoY
|
| EBIT |
5.80M
est: 4.13M (+40.3%)
|
10.59M
est: 7.67M (+38.1%)
|
9.92M
9.88M – 9.96M
+29.4% YoY
|
10.81M
10.68M – 10.95M
+9.0% YoY
|
11.63M
11.53M – 11.73M
+7.5% YoY
|
| Net Income |
7.08M
est: 5.09M (+38.9%)
|
5.93M
est: 7.41M (-19.9%)
|
11.35M
10.74M – 11.85M
+53.2% YoY
|
12.41M
12.23M – 12.60M
+9.3% YoY
|
13.89M
13.71M – 14.08M
+11.9% YoY
|
| SGA |
4.13M
est: 4.55M (-9.3%)
|
27.08M
est: 8.44M (+221.0%)
|
10.92M
10.87M – 10.96M
+29.4% YoY
|
11.90M
11.75M – 12.05M
+9.0% YoY
|
12.79M
12.69M – 12.90M
+7.5% YoY
|
| EPS |
0.02
est: 0.01 (+69.4%)
|
0.02
est: 0.02 (-18.5%)
|
0.03
0.03 – 0.03
+52.5% YoY
|
0.03
0.03 – 0.03
+9.8% YoY
|
0.04
0.04 – 0.04
+11.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Clayton Astles | Chief Executive Officer, MD & Executive Director | 939.3K | male |
| Brendan James Maher | Chief Financial Officer & Company Secretary | 465.2K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AHC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
